Wir sind mit live! Mehr erfahren

Amylyx Pharmaceuticals

AMLX

Börsenwert 3,31 Mrd. $

26,34 USD

-1,31

4,74 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

26,34

0,00

0 %

1 Tag

-4,74 %

5 Tage

-6,06 %

1 Monat

-19,28 %

3 Monate

54,76 %

6 Monate

48,56 %

Seit Jahresbeginn

130,65 %

1 Jahr

73,63 %

5 Jahre

45,77 %

10 Jahre

45,77 %

Profil: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Mitarbeiter: 136

Gesundheitswesen Arzneimittelhersteller – Spezialpräparate und Generika

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 41,9 %

Neutral 51,6 %

Negativ 6,5 %

Schaeffers Research

11 Stocks Most Likely to See a Short Squeeze Rally

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.

11 Stocks Most Likely to See a Short Squeeze Rally

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment

Schaeffers Research

10 Stocks With Massive Short Squeeze Potential

Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?

10 Stocks With Massive Short Squeeze Potential

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum.

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference.

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference

The Motley Fool

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?

20 stocks likely to lose money even if the bull market continues

Certain stocks are such poor bets that they are likely to lose ground even in bull markets.

20 stocks likely to lose money even if the bull market continues

The Motley Fool

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt